Capricor faces FDA advisory panel review of deramiocel in Duchenne muscular dystrophy - CAPR News | RalliesCapricor faces FDA advisory panel review of deramiocel in Duchenne muscular dystrophy
C
CAPR• FDA advisory committee review set for July 29
- Capricor will attend an FDA advisory committee meeting on July 29 to review its BLA for deramiocel in Duchenne muscular dystrophy.
CCapricor publishes advisory committee presentation on deramiocel clinical data in Duchenne muscular dystrophy
CAPR•
